Within-Individual Variation in Steady State Plasma Levels of Different Neuroleptics and Prolactin

1984 ◽  
Vol 144 (6) ◽  
pp. 625-629 ◽  
Author(s):  
R. G. McCreadie ◽  
Margaret Mackie ◽  
David H. Wiles ◽  
Aksel Jorgensen ◽  
Villy Hansen ◽  
...  

SummaryEleven male chronic schizophrenics were given, serially, oral pimozide, fluphenazine, and flupenthixol; the two latter were also given intramuscularly as decanoates in oil. Oral haloperidol was given before and after each drug. Analysis of variance of steady state plasma levels of the different neuroleptics showed considerable within-individual variation in such levels, probably due to differences in absorption and metabolism and between routes of administration. The findings suggest that if a patient fails to respond to one neuroleptic, there may be good pharmacokinetic reasons for switching him to another belonging to a different group, or for giving the same neuroleptic by a different route of administration. The study also showed that previous administration of one neurololeptic may influence the steady state level of another. The various neuroleptics produced different effects on plasma prolactin levels.

1989 ◽  
Vol 37 (2) ◽  
pp. 185-189 ◽  
Author(s):  
L. v. Bortel ◽  
R. Böhm ◽  
J. Mooij ◽  
P. Schiffers ◽  
K. H. Rahn

Nephron ◽  
1989 ◽  
Vol 53 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Susan H. Carchman ◽  
Domenic A. Sica ◽  
Judith Davis ◽  
James T. Crowe Jr. ◽  
Albert J. Wasserman ◽  
...  

2001 ◽  
Vol 62 (10) ◽  
pp. 812-817 ◽  
Author(s):  
Hsien-Yuan Lane ◽  
Michael W. Jann ◽  
Yue-Cune Chang ◽  
Chih-Chiang Chiu ◽  
Ming-Chyi Huang ◽  
...  

1956 ◽  
Vol 34 (2) ◽  
pp. 146-157 ◽  
Author(s):  
C. M. Southcott ◽  
S. K. Gandossi ◽  
A. D. Barker ◽  
H. E. Bandy ◽  
Hamish McIntosh ◽  
...  

The free and conjugated adrenal steroid fractions of peripheral plasma from12 normal human males were studied. Specimens were withdrawn before and after the administration of corticotropin. Hydrocortisone was identified chemically and some evidence was obtained for the presence of corticosterone. Hydrocortisone levels showed a marked but variable increase after corticotropin treatment. In some cases the administration of corticotropin resulted in the appearance of an unconjugated compound which may have been a tetrahydro derivative of cortisone or hydrocortisone. A method for studying the conjugated fraction was developed and preliminary data indicated that four components were present in some specimens after hydrolysis with β-glucuronidase. The level of these conjugates appeared to increase after treatment with corticotropin. In general, the response to a given dose of corticotropin showed considerable individual variation in the plasma levels of the components of both the free and conjugated corticosteroid fractions.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yazhou Li ◽  
Kelli L. Vaughan ◽  
David Tweedie ◽  
Jin Jung ◽  
Hee Kyung Kim ◽  
...  

AbstractThe time-dependent (30 min - day 84) plasma profile of PT320, a sustained-release (SR)-Exenatide formulation under clinical development for treatment of neurodegenerative disorders, was evaluated in nonhuman primates after a single subcutaneous dose and was compared to Bydureon. Exenatide release from PT320 exhibited a triphasic pharmacokinetic profile. An initial peak occurred at 3 hr post-administration, a secondary peak at 5 days, and achievement of Exenatide steady-state plasma levels from day 10–28. Systemic exposure increased across PT320 doses, and Exenatide levels were maintained above the therapeutic threshold prior to achieving a steady-state. In contrast, Exenatide release from Bydureon exhibited a biphasic profile, with an initial plasma peak at 3 hr, followed by a rapid decline to a sub-therapeutic concentration, and a gradual elevation to provide a steady-state from day 35–49. Exenatide total exposure, evaluated from the area under the time-dependent Exenatide concentration curve, was similar for equivalent doses of PT320 and Bydureon. The former, however, reached and maintained steady-state plasma Exenatide levels more rapidly, without dipping to a sub-therapeutic concentration. Both SR-Exenatide formulations proved well-tolerated and, following a well-regulated initial release burst, generated steady-state plasma levels of Exenatide, but with PT320 producing continuous therapeutic Exenatide levels and more rapidly reaching a steady-state.


Epilepsia ◽  
1984 ◽  
Vol 25 (4) ◽  
pp. 476-481 ◽  
Author(s):  
Roberto Riva ◽  
Fiorenzo Albani ◽  
Giovanni Ambrosetto ◽  
Manuela Contin ◽  
Pietro Cortelli ◽  
...  

2000 ◽  
Vol 20 (2) ◽  
pp. 141-149 ◽  
Author(s):  
Sachiyo Morita ◽  
Kazutaka Shimoda ◽  
Toshiyuki Someya ◽  
Yoshitaka Yoshimura ◽  
Kunitoshi Kamijima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document